-
公开(公告)号:US09028811B2
公开(公告)日:2015-05-12
申请号:US13431563
申请日:2012-03-27
CPC分类号: A61K35/14 , A61K35/28 , A61K45/06 , C12N5/0647 , C12N2501/02
摘要: The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and agents that stimulate the PGE2 pathway. Conversely, HSC modulators that prevent PGE2 synthesis decrease HSC numbers. HCS modulators may be used in vitro, in vivo, or ex vivo.
摘要翻译: 本发明提供了通过使用HCS调节剂调节造血干细胞群体的组合物和方法,所述HCS调节剂是根据特定适应症所希望的增加HSC数量或降低HSC数量的药剂。 例如,发现增加HSC数量的HSC调节剂包括前列腺素E2(PGE2)和刺激PGE2途径的试剂。 相反,防止PGE2合成的HSC调节剂降低HSC数。 HCS调节剂可以在体外,体内或体外使用。
-
公开(公告)号:US20110009370A1
公开(公告)日:2011-01-13
申请号:US12445986
申请日:2007-10-22
IPC分类号: A61K31/5575 , A61K31/5585 , A61K31/201 , A61K31/558 , A61K31/41 , A61K31/655 , A61P43/00 , C07C405/00 , C07D307/937 , C07C57/12 , C07D303/38 , C07D257/04 , C07C245/08 , C12N5/071
CPC分类号: A61K31/5575 , A61K31/201 , A61K31/404 , A61K31/41 , A61K31/557 , A61K31/558 , A61K31/5585 , A61K31/655 , A61K33/14
摘要: The present invention provides for compositions and methods for modulating tissue growth using tissue growth modulators, which are agents that either enhance or inhibit tissue growth as desired by a particular indication by modulating the PG or Wnt signaling pathways, or employing modulators of both PG and Wnt signaling pathways for a synergistic effect or highly selective effect.
摘要翻译: 本发明提供使用组织生长调节剂调节组织生长的组合物和方法,其是通过调节PG或Wnt信号传导途径增强或抑制特定指示所需的组织生长或使用PG和Wnt的调节剂的试剂 用于协同效应或高选择性效应的信号通路。
-
公开(公告)号:US20120189593A1
公开(公告)日:2012-07-26
申请号:US13431534
申请日:2012-03-27
CPC分类号: A61K35/14 , A61K35/28 , A61K45/06 , C12N5/0647 , C12N2501/02
摘要: The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and agents that stimulate the PGE2 pathway. Conversely, HSC modulators that prevent PGE2 synthesis decrease HSC numbers. HCS modulators may be used in vitro, in vivo, or ex vivo.
摘要翻译: 本发明提供了通过使用HCS调节剂调节造血干细胞群体的组合物和方法,所述HCS调节剂是根据特定适应症所希望的增加HSC数量或降低HSC数量的药剂。 例如,发现增加HSC数量的HSC调节剂包括前列腺素E2(PGE2)和刺激PGE2途径的试剂。 相反,防止PGE2合成的HSC调节剂降低HSC数。 HCS调节剂可以在体外,体内或体外使用。
-
公开(公告)号:US08168428B2
公开(公告)日:2012-05-01
申请号:US12294344
申请日:2007-04-26
CPC分类号: A61K35/14 , A61K35/28 , A61K45/06 , C12N5/0647 , C12N2501/02
摘要: The present invention provides for compositions and methods for modulating hematopoietic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and agents that stimulate the PGE2 pathway. Conversely, HSC modulators that prevent PGE2 synthesis decrease HSC numbers. HCS modulators may be used in vitro, in vivo, or ex vivo.
摘要翻译: 本发明提供了通过使用HCS调节剂调节造血干细胞群体的组合物和方法,所述HCS调节剂是根据特定适应症所希望的增加HSC数量或降低HSC号的试剂。 例如,发现增加HSC数量的HSC调节剂包括前列腺素E2(PGE2)和刺激PGE2途径的试剂。 相反,防止PGE2合成的HSC调节剂降低HSC数。 HCS调节剂可以在体外,体内或体外使用。
-
公开(公告)号:US08563310B2
公开(公告)日:2013-10-22
申请号:US13431499
申请日:2012-03-27
CPC分类号: A61K35/14 , A61K35/28 , A61K45/06 , C12N5/0647 , C12N2501/02
摘要: The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and agents that stimulate the PGE2 pathway. Conversely, HSC modulators that prevent PGE2 synthesis decrease HSC numbers. HCS modulators may be used in vitro, in vivo, or ex vivo.
摘要翻译: 本发明提供了通过使用HCS调节剂调节造血干细胞群体的组合物和方法,所述HCS调节剂是根据特定适应症所希望的增加HSC数量或降低HSC数量的药剂。 例如,发现增加HSC数量的HSC调节剂包括前列腺素E2(PGE2)和刺激PGE2途径的试剂。 相反,防止PGE2合成的HSC调节剂降低HSC数。 HCS调节剂可以在体外,体内或体外使用。
-
公开(公告)号:US09402852B2
公开(公告)日:2016-08-02
申请号:US12445986
申请日:2007-10-22
IPC分类号: A61K31/557
CPC分类号: A61K31/5575 , A61K31/201 , A61K31/404 , A61K31/41 , A61K31/557 , A61K31/558 , A61K31/5585 , A61K31/655 , A61K33/14
摘要: The present invention provides for compositions and methods for modulating tissue growth using tissue growth modulators, which are agents that either enhance or inhibit tissue growth as desired by a particular indication by modulating the PG or Wnt signaling pathways, or employing modulators of both PG and Wnt signaling pathways for a synergistic effect or highly selective effect.
摘要翻译: 本发明提供使用组织生长调节剂调节组织生长的组合物和方法,其是通过调节PG或Wnt信号传导途径增强或抑制特定指示所需的组织生长或使用PG和Wnt的调节剂的试剂 用于协同效应或高选择性效应的信号通路。
-
公开(公告)号:US08551782B2
公开(公告)日:2013-10-08
申请号:US13431534
申请日:2012-03-27
CPC分类号: A61K35/14 , A61K35/28 , A61K45/06 , C12N5/0647 , C12N2501/02
摘要: The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and agents that stimulate the PGE2 pathway. Conversely, HSC modulators that prevent PGE2 synthesis decrease HSC numbers. HCS modulators may be used in vitro, in vivo, or ex vivo.
摘要翻译: 本发明提供了通过使用HCS调节剂调节造血干细胞群体的组合物和方法,所述HCS调节剂是根据特定适应症所希望的增加HSC数量或降低HSC数量的药剂。 例如,发现增加HSC数量的HSC调节剂包括前列腺素E2(PGE2)和刺激PGE2途径的试剂。 相反,防止PGE2合成的HSC调节剂降低HSC数。 HCS调节剂可以在体外,体内或体外使用。
-
公开(公告)号:US20120189594A1
公开(公告)日:2012-07-26
申请号:US13431563
申请日:2012-03-27
CPC分类号: A61K35/14 , A61K35/28 , A61K45/06 , C12N5/0647 , C12N2501/02
摘要: The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and agents that stimulate the PGE2 pathway. Conversely, HSC modulators that prevent PGE2 synthesis decrease HSC numbers. HCS modulators may be used in vitro, in vivo, or ex vivo.
摘要翻译: 本发明提供了通过使用HCS调节剂调节造血干细胞群体的组合物和方法,所述HCS调节剂是根据特定适应症所希望的增加HSC数量或降低HSC数量的药剂。 例如,发现增加HSC数量的HSC调节剂包括前列腺素E2(PGE2)和刺激PGE2途径的试剂。 相反,防止PGE2合成的HSC调节剂降低HSC数。 HCS调节剂可以在体外,体内或体外使用。
-
公开(公告)号:US20120189592A1
公开(公告)日:2012-07-26
申请号:US13431499
申请日:2012-03-27
CPC分类号: A61K35/14 , A61K35/28 , A61K45/06 , C12N5/0647 , C12N2501/02
摘要: The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and agents that stimulate the PGE2 pathway. Conversely, HSC modulators that prevent PGE2 synthesis decrease HSC numbers. HCS modulators may be used in vitro, in vivo, or ex vivo.
摘要翻译: 本发明提供了通过使用HCS调节剂调节造血干细胞群体的组合物和方法,所述HCS调节剂是根据特定适应症所希望的增加HSC数量或降低HSC数量的药剂。 例如,发现增加HSC数量的HSC调节剂包括前列腺素E2(PGE2)和刺激PGE2途径的试剂。 相反,防止PGE2合成的HSC调节剂降低HSC数。 HCS调节剂可以在体外,体内或体外使用。
-
公开(公告)号:US20110206781A1
公开(公告)日:2011-08-25
申请号:US12994527
申请日:2009-05-28
IPC分类号: A61K33/00 , C12N5/0789 , A61K31/197 , A61K31/517 , A61K31/138 , A61K31/4418 , A61K31/7048 , A61K31/198 , A61K31/295 , A61K31/165 , A61K31/4985 , A61K31/137 , A61K31/44 , A61K31/353 , A61K31/216 , A61P7/00
CPC分类号: A61K31/00 , A61K31/04 , C12N5/0647 , C12N2501/03 , C12N2506/02 , C12N2506/11 , C12N2506/45
摘要: Described herein are methods, compositions and kits related to manipulating hematopoietic stem cells (HSC) and more particularly to methods, compositions and kits related to increasing the number of hematopoietic stem cells in vitro, ex vivo and/or in vivo. Also described are methods, compositions and kits related to making an expanded population of HSC and methods, compositions and kits related to using the expanded population of HSC. For example, HSC growth may be enhanced by contacting the nascent stem cells or HSC with an agent that stimulates the nitric oxide signaling pathway.
摘要翻译: 本文描述了与操纵造血干细胞(HSC)相关的方法,组合物和试剂盒,更具体地涉及与体外,离体和/或体内增加造血干细胞数量有关的方法,组合物和试剂盒。 还描述了与制造HSC的扩大群体相关的方法,组合物和试剂盒以及与使用HSC的扩展群体相关的方法,组合物和试剂盒。 例如,可以通过使新生干细胞或HSC与刺激一氧化氮信号通路的药物接触来增强HSC生长。
-
-
-
-
-
-
-
-
-